YOLFTbeta
68

BrightGene Bio Medical Technology C

688166 · SHG · Healthcare / Biotechnology

28.90CNY-1.10 (-3.67%)

Price History

Full chart

Market Stats

Previous Close30.00
Open30.05
Day Range28.86 – 30.20
52-Week Range28.74 – 72.88
Volume7.86M
Market Cap15.61B
P/E (TTM)155.70
Forward P/E0.00
EPS0.23
Dividend Yield0.04%
Beta0.23
50-Day Avg36.16
200-Day Avg45.40

About

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jiandong Yuan
  • Employees1.20K
  • HeadquartersBuilding C25-28, Suzhou, China, 215123, China
  • Websitehttps://www.bright-gene.com

Leadership

  • Mr. Jiandong YuanChairman & GM · b. 1970
  • Mr. Yuanlai ZouCFO & Director · b. 1971
  • Mr. Kai LiEmployee Representative Director & Deputy GM · b. 1976
  • Ms. Nan DingBoard Secretary & Director · b. 1991
  • Fangsheng LiuAccounting Supervisor

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue200.92M316.77M407.50M503.16M785.38M1.05B1.02B1.18B1.28B1.22B
Growth (%)-+57.66%+28.64%+23.47%+56.09%+34.00%-3.33%+15.94%+8.74%-4.59%
Cost of Revenue85.04M130.10M169.30M180.91M353.99M460.67M376.30M521.41M544.95M601.61M
Gross Profit115.88M186.67M238.20M322.25M431.39M591.74M641.03M658.10M737.60M622.03M
Gross Margin57.67%58.93%58.45%64.04%54.93%56.23%63.01%55.79%57.51%50.83%
Operating Expense97.20M130.12M151.41M196.58M223.12M317.34M376.37M404.50M486.77M511.83M
Operating Income18.68M56.55M86.79M125.66M208.26M274.40M264.66M253.60M250.83M110.20M
Operating Margin9.30%17.85%21.30%24.97%26.52%26.07%26.01%21.50%19.56%9.01%
EBITDA-69.47M97.61M146.33M223.57M308.65M316.38M311.25M321.04M236.32M
EBITDA Margin-21.93%23.95%29.08%28.47%29.33%31.10%26.39%25.03%19.31%
Net Income17.06M45.88M73.20M111.08M169.88M243.95M239.62M202.47M189.17M54.51M
Net Income Margin8.49%14.48%17.96%22.08%21.63%23.18%23.55%17.17%14.75%4.46%
R&D53.58M80.81M96.12M124.88M140.84M173.29M207.02M248.59M297.45M304.95M
R&D as % of Total Revenue26.66%25.51%23.59%24.82%17.93%16.47%20.35%21.08%23.19%24.92%
Interest Expense00413.32K225.05K2.04M9.70M23.71M44.42M52.44M62.96M
Interest Expense % of Total Revenue0.00%0.00%0.10%0.04%0.26%0.92%2.33%3.77%4.09%5.15%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets384.19M524.92M878.37M1.42B1.83B2.97B4.66B5.03B5.16B5.82B
Total Liabilities164.05M78.89M105.52M108.21M395.23M1.23B2.42B2.61B2.73B2.98B
Total Equity220.15M446.02M772.85M1.31B1.43B1.68B2.19B2.37B2.39B2.52B
Cash41.99M103.77M206.45M564.97M339.53M336.84M1.18B998.05M765.35M961.06M
Net Debt-----565.36M835.26M773.75M915.19M537.51M

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow29.73M35.77M63.99M61.33M155.43M176.08M311.26M194.77M245.56M325.19M
Investing Cash Flow-36.58M-80.93M-212.48M-155.99M-541.92M-889.84M-871.58M---
Financing Cash Flow-109.86M249.59M439.76M185.73M703.72M1.36B---
Capital Expenditure36.58M83.70M112.47M89.54M355.27M909.66M726.73M389.33M257.20M453.41M
Free Cash Flow--47.94M-48.49M-28.21M-199.84M-733.59M-415.47M-185.08M-11.64M-128.22M
Dividends Paid3.49M1.94M35.40M35.40M35.40M54.30M100.10M113.75M135.73M117.60M
FCF to OCF--134.02%-75.77%-45.99%-128.57%-416.63%-133.48%-95.03%-4.74%-39.43%
Dividend Paid to FCF--4.04%-73.01%-125.51%-17.71%-7.40%-24.09%-61.46%-1166.11%-91.72%

Earnings

Report DateOct 30, 2019Feb 25, 2020Apr 19, 2020Aug 17, 2020Oct 22, 2020Feb 24, 2021Apr 28, 2021Aug 24, 2021Oct 25, 2021Feb 25, 2022Apr 27, 2022Aug 24, 2022Oct 27, 2022Apr 24, 2023
EPS Estimate0.00-------------
EPS Actual0.040.120.080.100.120.120.120.140.170.160.150.130.210.10
Surprise--------------
TimingPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap15.61B
Enterprise Value17.07B
Trailing P/E155.70
Forward P/E0.00
Price / Sales11.44
Price / Book5.18
EPS0.23
Book Value7.01
Revenue (TTM)1.36B
Gross Profit (TTM)720.39M
EBITDA267.96M
Profit Margin7.06%
Operating Margin21.13%
Return on Equity3.32%
Return on Assets1.24%
Shares Outstanding435.79M
Shares Float265.74M
Beta0.23
Dividend Yield0.04%
Dividend Rate0.02
Payout Ratio6.96%

Dividends

20231×
0.11Jun 15, 2023
20221×
0.12Jun 16, 2022
20211×
0.08May 11, 2021
20201×
0.08Jun 8, 2020